Get started
Keyword

CA19-9

Description: A carbohydrate antigen used as a tumor marker, particularly in the clinical assessment of pancreatic and other gastrointestinal cancers.
Wikidata ID: wiki/Q182517
OpenAlex ID: keywords/ca19-9
Hepatogastroenterology
2011 · Yan Li, Ying Yang, et al. · Hepatogastroenterology · 2,435
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
2006 · Gershon Y. Locker, Stanley Hamilton, et al. · Journal of Clinical Oncology · 1,593
Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study
2004 · William R. Brugge, Kent Lewandrowski, et al. · Gastroenterology · 1,386
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
2013 · Yizhou Wang, Jun Li, et al. · Journal of Clinical Oncology · 1,058
Gemcitabine Plus nab -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
2011 · Daniel D. Von Hoff, Ramesh K. Ramanathan, et al. · Journal of Clinical Oncology · 1,045
Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
2014 · Maximilian Bockhorn, Faik G. Uzunoglu, et al. · Surgery · 969
Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer
2006 · K.S. Goonetilleke, A.K. Siriwardena · European Journal of Surgical Oncology · 878
Circulating Exosomal microRNAs as Biomarkers of Colon Cancer
2014 · Hiroko Ogata-Kawata, Masashi Izumiya, et al. · PLoS ONE · 809
PDF
International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
2017 · Shuji Isaji, Shugo Mizuno, et al. · Pancreatology · 801
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.
2012 · Umashankar K Ballehaninna, Ronald S Chamberlain · PubMed · 701
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
2015 · D. Goldstein, R. H. El-Maraghi, et al. · JNCI Journal of the National Cancer Institute · 658
Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis
2005 · Laurens A. van der Waaij, Hendrik M. van Dullemen, et al. · Gastrointestinal Endoscopy · 612
Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate
2004 · Caio M. Rocha Lima, Mark R. Green, et al. · Journal of Clinical Oncology · 588
The clinical utility of the CA 19-9 tumor-associated antigen.
1990 · W Steinberg · PubMed · 582
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
2013 · Dung T. Le, Eric Lutz, et al. · Journal of Immunotherapy · 564
Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma
2006 · Cristina R. Ferrone, Dianne M. Finkelstein, et al. · Journal of Clinical Oncology · 554
Value of Serum IgG4 in the Diagnosis of Autoimmune Pancreatitis and in Distinguishing It From Pancreatic Cancer
2007 · Amaar Ghazale, Suresh T. Chari, et al. · The American Journal of Gastroenterology · 551
Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
2014 · Joseph M. Herman, Daniel T. Chang, et al. · Cancer · 542
PDF
Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association
2013 · Hideaki Shimada, Tamaki Noie, et al. · Gastric Cancer · 539
PDF
Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.
1983 · B C Del Villano, S Brennan, et al. · Clinical Chemistry · 506
MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer
2014 · Nicolai A. Schultz, Christian Dehlendorff, et al. · JAMA · 451
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
2020 · Guopei Luo, Kaizhou Jin, et al. · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 442
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis
2000 · Anand H. Patel, Denise M. Harnois, et al. · The American Journal of Gastroenterology · 425
Pancreatic Cancer Surgery in the New Millennium
2011 · Werner Hartwig, Thilo Hackert, et al. · Annals of Surgery · 412
A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis
2010 · Rui Liu, Chunni Zhang, et al. · European Journal of Cancer · 408
Works count: 23,920
Citation count: 268,100
Year
Topic
Type